June 2, 2007 |
Donkey meat with garlic juice and deep-fried duck bills aren't Dajun Yang's favorite fare. But while accompanying two U.S. colleagues on a recent trip to Beijing, he made sure they were exposed to cuisine they couldn't find back home. Culinary tour guide is just one of Yang's many unofficial jobs. As the head of the China subsidiary of San Diego-based Ascenta Therapeutics Inc.
April 15, 2007 |
Kevin Sharer has a thing for maverick war heroes. In his sunlit office in Thousand Oaks, a massive portrait of the often-flamboyant Gen. George Armstrong Custer hangs across from his desk. It complements one of English naval great Horatio Nelson, renowned for defying orders. Sharer has a military background himself, gained as an engineer on fast-attack Navy nuclear submarines during the Cold War. These days, at troubled Amgen Inc., he's emulating his risk-taking heroes more than ever.
March 13, 2007 |
A federal judge Monday overturned the Bush administration's 2005 approval of genetically engineered alfalfa seeds and stopped their sale for now, in what activists hailed as the first ban on selling such crops. U.S. District Judge Charles R. Breyer in San Francisco found that the U.S. Department of Agriculture failed to adequately conduct an environmental impact study before approving them for sale.
March 12, 2007 |
WE count on them to be strong and supportive, flexible and accommodating, willing to go the extra mile even when we load them down more than we should. Our knees. We put them through their paces, so to speak, every day. No wonder that, every now and then, they fall down on the job. Treatments for needy knees generally fit into three categories, says Dr.
December 11, 2006 |
Ten years after genetically engineered crops were first planted commercially in the United States, Americans remain ill-informed about and uncomfortable with biotech food, according to the fifth annual survey on the topic, released Wednesday. People vastly underestimate how much gene-altered food they are already consuming; lean toward wanting greater regulation of such crops; and have less faith than ever that the Food and Drug Administration will provide accurate information, the survey found.
December 6, 2006 |
Amgen Inc., the Thousand Oaks-based biotech behemoth, has been a shining star in the drug industry for more than two decades. Recently, it isn't burning so brightly. This morning, Congress begins hearings about cost and safety concerns around two of the company's top-selling drugs, Epogen and Aranesp, which are used to treat nearly 2 1/2 million dialysis and cancer patients with anemia in the U.S. each year.
November 26, 2006 |
In myth, seeds of rice came to China tied to a dog's tail, rescuing the people from famine after a time of severe floods. Ancient writings held that grains -- rice foremost among them -- were more precious than jade or pearls. Now China is deliberating whether to allow farmers to plant rice seed born of biotechnology, modified by scientists in the laboratory.
November 11, 2006 |
What do you call a drug that costs as much as $100,000 a year but doesn't face competition? If you're a consumer footing the bill, you might call it an unfair monopoly. If you're the biotechnology company selling the medication, it's a money machine that needs to be protected at all costs. All this could change soon.
November 10, 2006 |
Genentech Inc. intends to acquire tiny biotechnology company Tanox Inc. for $919 million in cash, the South San Francisco-based drug maker announced Thursday. The acquisition would help streamline a three-way partnership the two companies share with Swiss firm Novartis in the development and commercialization of the asthma-fighting drug Xolair, which was created by Tanox.
October 20, 2006 |
A Monrovia-based start-up on Thursday became the latest participant in a biotech consolidation wave that is seeing bigger players investing in or buying smaller companies. And much of that activity is in California, where the biomedical industry has become one of the state's fastest-growing industries, according to a report released Thursday. The trend is driven by bigger companies needing to keep their drug development pipelines filled with new products. That logic made Xencor Inc.